Company / Working Capital per Share
Aclaris Therapeutics, Inc. Working Capital per Share History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital per Share
$0.63
FY2025
5-year range
$0.63 / $4.04
FY2021-FY2025
Trend
-52.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital per Share has declined for 4 consecutive years, from $4.04 in FY2021 to $0.63 in FY2025.
Based on SEC 10-K filings.
0.63 in FY2025 with a 5-year CAGR of -9.4%.
Declined from $1.47 to $0.63 over the past 2 years.
Working Capital per Share over time
Growth rates
- 3-Year CAGR
- -43.2%
- 5-Year CAGR
- -9.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- Aclaris Therapeutics, Inc.'s working capital per share has declined for 4 consecutive years.
- In FY2025, working capital per share decreased 52.9% year-over-year.
- Peak working capital per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working Capital per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.63 | -52.9% |
| FY2024 | $1.33 | -9.3% |
| FY2023 | $1.47 | -57.1% |
| FY2022 | $3.42 | -15.2% |
| FY2021 | $4.04 | +293.0% |
| FY2020 | $1.03 | -31.0% |
| FY2019 | $1.49 | -69.8% |
| FY2018 | $4.93 | -31.5% |
| FY2017 | $7.19 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026